logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

BRCA1/2+ advanced breast cancer: talazoparib fails to extend OS vs chemo in final EMBRACA results

But patient-reported outcomes were better with talazoparib.